2008
Imatinib mesylate (Gleevec®) in advanced breast cancer-expressing C-Kit or PDGFR-β: clinical activity and biological correlations
Cristofanilli M, Morandi P, Krishnamurthy S, Reuben JM, Lee B, Francis D, Booser DJ, Green MC, Arun BK, Pusztai L, Lopez A, Islam R, Valero V, Hortobagyi GN. Imatinib mesylate (Gleevec®) in advanced breast cancer-expressing C-Kit or PDGFR-β: clinical activity and biological correlations. Annals Of Oncology 2008, 19: 1713-1719. PMID: 18515258, PMCID: PMC2735063, DOI: 10.1093/annonc/mdn352.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntineoplastic AgentsBenzamidesBreast NeoplasmsBreast Neoplasms, MaleCarcinoma, Ductal, BreastFemaleHumansImatinib MesylateImmunologic FactorsMaleMiddle AgedNeoplasm MetastasisPiperazinesProspective StudiesProtein Kinase InhibitorsProto-Oncogene Proteins c-kitPyrimidinesReceptor, Platelet-Derived Growth Factor betaConceptsMetastatic breast cancerPlatelet-derived growth factor receptorImatinib mesylateC-kitDisease progressionClinical activityB-fibroblast growth factorGrowth factorMedian overall survivalSerious adverse eventsPotential immunosuppressive effectsInterferon-gamma productionVascular endothelial growth factorAngiogenesis-related cytokinesEndothelial growth factorNovel molecular therapiesC-kit expressionGrowth factor receptorAdverse eventsObjective responseOverall survivalTreat analysisDismal prognosisMedian timeImmunomodulatory effects
2004
Targeted Therapies for Cancer 2004
Ross JS, Schenkein DP, Pietrusko R, Rolfe M, Linette GP, Stec J, Stagliano NE, Ginsburg GS, Symmans WF, Pusztai L, Hortobagyi GN. Targeted Therapies for Cancer 2004. American Journal Of Clinical Pathology 2004, 122: 598-609. PMID: 15487459, DOI: 10.1309/5cwpu41afr1vym3f.Peer-Reviewed Original ResearchConceptsBcr/abl-positive chronic myelogenous leukemiaNon-small cell lung cancerEmergence of trastuzumabMetastatic colorectal cancerMetastatic breast cancerCell lung cancerRoute of administrationChronic myelogenous leukemiaProteasome inhibitor bortezomibEpidermal growth factor receptor (EGFR) geneNew therapeutic agentsEpidermal growth factor receptorSpecific genetic defectsTargeted anticancer therapiesGrowth factor receptorAgent bevacizumabGrowth factor receptor geneMolecular diagnosticsColorectal cancerCancer patientsLung cancerHematologic malignanciesImatinib mesylateTargeted therapyBreast cancer